COGNITIVE-SYSTEMS
10.3.2021 11:02:12 CET | Business Wire | Press release
Cognitive Systems Corp. announced today an integration with Airties to offer its patented WiFi Motion technology across Airties’ portfolio of WiFi 6 solutions. Cognitive’s WiFi Motion will make it easier than ever for service providers to access this revolutionary sensing technology.
Over the past six years, Cognitive Systems has designed, developed, and implemented the first and most sophisticated WiFi-enabled motion sensing software on the market. WiFi Motion leverages connected IoT devices to turn the entire home into a motion-sensing network, introducing an innovative way to use WiFi. With 37 ISPs currently offering WiFi Motion around the globe, millions of homes already have access to this new service and its growing number of applications.
“Service providers are looking for new ways to differentiate from competitors and retain customers. Our priority is providing smart WiFi solutions that offer value beyond connectivity,” said Taj Manku, Co-Founder and CEO of Cognitive Systems. “Like us, Airties aims to shape the next generation of wireless solutions and see the possibilities for motion sensing, from smarter home monitoring to a higher standard of eldercare. We’re doing the legwork with their Wi-Fi 6 portfolio to get WiFi Motion ready for some forward-thinking Airties service providers who want to offer these benefits to their customers as soon as possible.”
Cognitive Systems and Airties share a commitment to staying ahead of the market, both by being active members of the Wireless Broadband Alliance (WBA) and closely following emerging trends. In addition to the current home monitoring capabilities, WiFi Motion’s highly anticipated eldercare solution will bring peace of mind to caregivers by providing discreet wellness monitoring without the need for cameras or wearable devices. The market for remote wellness monitoring products is growing rapidly. Soon customers will be able to receive notifications and gain valuable insights into not only their homes but also the homes of loved ones.
“As a pioneer and leader in Wi-Fi sensing, we are pleased to be working with Cognitive Systems on new Wi-Fi 6 solutions,” said Metin Taskin, Co-Founder and CTO of Airties. “Cognitive’s product roadmap has a realistic game plan for both implementation and longevity. The integration of WiFi Motion and Airties can enable service providers to offer innovative value-add Wi-Fi services to their customers.”
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
About Airties
Founded in 2004, Airties is the most widely deployed provider of managed in-home Wi-Fi solutions to operators around the globe. The company offers Smart Wi-Fi software, a cloud-based management platform, and Mesh extenders. Service providers turn to Airties for the design, implementation, and ongoing optimization of their customers’ broadband experience. With an installed base of over 30 million homes, Airties’ customers include: Altice USA, AT&T, Singtel, Sky, Telia, Telstra, and many others. More information is available at www.Airties.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom